Trials / Recruiting
RecruitingNCT05803551
A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients
A Phase II Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effects of Ketamine Infusions in Clinically Depressed ICU Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to study the effects of intravenous ketamine infusions for the treatment of patients with depressive symptoms in intensive care unit (ICU).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketamine Hydrochloride | Intravenous 0.5 mg/kg infusions of ketamine for three consecutive days, 24 hours apart, with no more than 1mg/kg or 60 mg/day regardless of body weight |
| DRUG | Placebo | Intravenous 0.9% saline infusions for three consecutive days. |
Timeline
- Start date
- 2025-07-07
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2023-04-07
- Last updated
- 2025-08-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05803551. Inclusion in this directory is not an endorsement.